Effect of anti-estrogens on the androgen receptor activity and cell proliferation in prostate cancer cells

Urological Research

Volumn 32, Issue 6, 2004, Pages 406-410

  Kawashima, Hidenori ^a   Tanaka, Tomoaki ^a   Cheng, Jed Sian ^a   Sugita, Syozo ^a   Ezaki, Kazuyoshi ^a   Kurisu, Takeshi ^a   Nakatani, Tatsuya ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Androgen receptor; Anti estrogens; Estrogen; Estrogen receptors; Prostate cancer

Indexed keywords

ALLYLESTRENOL; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIESTROGEN; CHLORMADINONE ACETATE; DIETHYLSTILBESTROL; FLUTAMIDE; FULVESTRANT; TAMOXIFEN; TOREMIFENE;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CODON; CONTROLLED STUDY; DRUG EFFECT; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TRANSACTIVATION;

CELL LINE, TUMOR; CELL PROLIFERATION; ESTRADIOL; ESTROGEN ANTAGONISTS; HUMANS; MALE; MUTATION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TOREMIFENE; TRANS-ACTIVATION (GENETICS);

EID: 12444249992     PISSN: 03005623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00240-004-0424-8     Document Type: Article

References (23)

1. Griffiths K, Denis LJ, Behre HE, Bracke M, Krieg M, Kyprianou N, Lee C, Mahler CH, Petritisch P, Prezioso D, Prins GS, Tunn U, Vermeulen A (2000) Estrogens and prostatic disease. Prostate 45: 87
2. Bonkhoff H, Fixemer T, Hunsicker I, Remberger K (1999) Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am J Pathol 155: 641
3. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J-A (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 93: 5925
4. Chang WY, Prins GS (1999) Estrogen receptor-β: implication for the prostate gland. Prostate 40: 115
5. Lau K-M, LaSpina M, Long J, Ho S-M (2000) Expression of estrogen receptor (ER)-α and ER-β in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res 60: 3175
6. Latil A, Bieche I, Vidaud D, Lidereau R, Berthon P, Cussenot O, Vidaud M (2001) Evaluation of androgen, estrogen (ERα and ERβ), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 61: 1919
7. Nanni S, Narducci M, Pietra LD, Moretti F, Grasselli A, De Carli P, Sacchi A, Pontecorvi A, Farsetti A (2002) Signaling through estrogen receptor modulates telomerase activity in human prostate cancer. J Clin Invest 110: 219
8. Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS (2002) Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 62: 1370
9. Huynh H, Alpert L, Alaoui-Jamali MA, Ng CY, Chan TWM (2001) Co-administration of finasteride and the pure anti-oestrogen ICI182,780 act synergistically in modulating the IGF system in rat prostate. J Endocrinol 171: 109
10. Kim IY, Kim B-C, Seong DH, Lee DK, Seo J-M, Hong YJ, Kim H-T, Morton RA, Kim S-J (2002) Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Res 62: 5365
11. Rohlff C, Blagosklonny MV, Kyle E, Kesari A, Kim IY, Zelner DJ, Hakim F, Trepel J, Bergan RC (1998) Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21 (waf1/cip1). Prostate 37: 51
12. Bergan RC, Reed E, Myers CE, Headlee D, Brawley O, Cho H-K, Figg WD, Tompkins A, Linehan WM, Kohler D, Steinberg SM, Blagosklonny MV (1999) A phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. Clin Cancer Res 5: 2366
13. Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ (1998) A phase II trial of oral diethylstilbestrol as a second-line hormonal agent in advanced prostate cancer. Urology 52: 257
14. Weihua Z, Mäkelä S, Andersson LC, Salmi S, Saji S, Webster JI, Jensen EV, Nilsson S, Warner M, Gustafsson J-Å (2001) A role for estrogen receptor β in the regulation of growth of the ventral prostate. Proc Natl Acad Sci U S A 98: 6330
15. Weihua Z, Lathe R, Warner M, Gustafsson J-Å (2002) An endocrine pathway in the prostate, ERβ, AR, 5α-androstane-3β, 17β-diol, and CYP7B1, regulates prostate growth. Proc Natl Acad Sci U S A 99: 13589
16. Horvath LG, Henshall SM, Lee C-S, Head DR, Quinn DI, Makela S, Delprado W, Golovsky D, Brenner PC, O'Neill G, Kooner R, Stricker PD, Grygiel JJ, Gustafsson J-Å, Sutherland RL (2001) Frequent loss of estrogen receptor-β expression in prostate cancer. Cancer Res 61: 5331
17. Leav I, Lau K-M, Adams JY, McNeal JE, Taplin M-E, Wang J, Singh H, Ho S-M (2001) Comparative studies of the estrogen receptors β and α and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 159: 79
18. Fixemer T, Remberger K, Bonkhoff H (2003). Differential expression of the estrogen receptor β (ERβ) in human prostate tissue, premalignant changes, and in primary, metastatic and recurrent prostatic adenocarcinoma. Prostate 54: 79
19. Torlakovic E, Lilleby W, Torlakovic G, Fossa SD, Chibber R (2002) Prostate carcinoma expression of estrogen receptor-β as detected by PPG5/10 antibody has positive association with primary Gleason grade and Gleason score. Hum Pathol 33: 646
20. Marcelli M, Weigel NL, Lamb DJ (2000) Steroid receptors in prostate cancer development and progression. In: Ethier SP (ed) Endocrine oncology. Humana, Totowa, p 255
21. Veldscholte J, Ris-Stalper C, Kuiper GGJM, Jenster G, Berrevoets C, Claassen E, Van Rooij HCJ, Trapman J, Brinkmann AO, Mulder E (1990) A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173: 534
22. Taplin M-E, Bubley GJ, Ko Y-J, Small EJ, Upton M, Rajeshkumar B, Balk SP (1999) Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59: 2511
23. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M (2003) Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 63: 149